About Charlotte Parker

This author has not yet filled in any details.
So far Charlotte Parker has created 2907 blog entries.

HPV: The gender-neutral killer in need of prevention among men

Source: CNN Author: Dominic Rech In July 2014, Phil Rech, then 59, was diagnosed with tonsil cancer. "I had got a lump in my neck. I had the tonsils out, and within the next few days, I was having radical neck dissection," he said. "Then I had six weeks of intensive, targeted radiotherapy. The burning effect towards the end of the treatment became very painful." The therapy involved a radiotherapy mask, molded to the shape of his face, that went over his head as radiotherapy was beamed in, targeting the cancer. The discovery of his cancer not only startled him, it startled everyone who knew him. Phil is my dad, and to our family, he had always been healthy: He doesn't smoke, he rarely drinks alcohol, and he generally stays fairly fit. But that's not how cancer works. At the time of the diagnosis, Phil didn't question how or what could have caused his cancer, as he focused on getting better. Like many men in the UK and around the world, he wasn't aware of a group of viruses that were a threat, human papillomavirus or HPV, which were eventually connected to his cancer. "To discover it was linked to HPV was a massive shock," he said. "There was a lot of speculation over what could have caused it. To discover it was that, was certainly a surprise. I didn't really know it was a threat to me." A cancerous virus HPV is a group of 150 related viruses that [...]

2018-07-28T15:15:04-07:00July, 2018|OCF In The News|

Health Insurers Are Vacuuming Up Details About You — And It Could Raise Your Rates

Source: National Public Radio Author: Marshall Allen To an outsider, the fancy booths at a June health insurance industry gathering in San Diego, Calif., aren't very compelling: a handful of companies pitching "lifestyle" data and salespeople touting jargony phrases like "social determinants of health." But dig deeper and the implications of what they're selling might give many patients pause: a future in which everything you do — the things you buy, the food you eat, the time you spend watching TV — may help determine how much you pay for health insurance. With little public scrutiny, the health insurance industry has joined forces with data brokers to vacuum up personal details about hundreds of millions of Americans, including, odds are, many readers of this story. The companies are tracking your race, education level, TV habits, marital status, net worth. They're collecting what you post on social media, whether you're behind on your bills, what you order online. Then they feed this information into complicated computer algorithms that spit out predictions about how much your health care could cost them. Are you a woman who recently changed your name? You could be newly married and have a pricey pregnancy pending. Or maybe you're stressed and anxious from a recent divorce. That, too, the computer models predict, may run up your medical bills. Are you a woman who has purchased plus-size clothing? You're considered at risk of depression. Mental health care can be expensive. Low-income and a minority? That means, the data [...]

2018-07-17T09:40:59-07:00July, 2018|OCF In The News|

Cancer: Can testosterone improve patients’ quality of life?

Source: Medical News Today Author: Maria Cohut Cachexia is a condition characterized by loss of body mass — including muscular atrophy — that is usually accompanied by severe weakness and fatigue. Many people who go through cancer experience this. Studies have noted that "[a]pproximately half of all patients with cancer experience cachexia," severely impairing their quality of life. It appears to be "responsible for the death of 22 [percent] of cancer patients." What exactly causes this condition — which appears in some patients but not in others — remains unclear, and options to manage and address it are scarce. But recently, researchers from the University of Texas Medical Branch in Galveston — led by Dr. Melinda Sheffield-Moore, from the Department of Health and Kinesiology — have been investigating the potential of administering testosterone in addition to chemotherapy in order to ameliorate the impact of cachexia. "We hoped to demonstrate these [cancer] patients [who received testosterone treatment] would go from not feeling well enough to even get out of bed to at least being able to have some basic quality of life that allows them to take care of themselves and receive therapy." Dr. Melinda Sheffield-Moore The researchers' findings — now published in the Journal of Cachexia, Sarcopenia and Muscle — confirm that administering testosterone to individuals experiencing cachexia can, in fact, improve their quality of life to some extent, by restoring some independence of movement. Adjuvant testosterone shows promise The most widely used approach to manage cachexia is special nutrition treatments, but [...]

2018-07-17T09:30:54-07:00July, 2018|OCF In The News|

Smoking hits new low; about 14 percent of US adults light up

Source: https://flipboard.com Author: Mike Strobbe, AP Medical Writer NEW YORK (AP) — Smoking in the U.S. has hit another all-time low. About 14 percent of U.S adults were smokers last year, down from about 16 percent the year before, government figures show. There hadn't been much change the previous two years, but it's been clear there's been a general decline and the new figures show it's continuing, said K. Michael Cummings of the tobacco research program at Medical University of South Carolina. "Everything is pointed in the right direction," including falling cigarette sales and other indicators, Cummings said. The new figures released Tuesday mean there are still more than 30 million adult smokers in the U.S., he added. Teens are also shunning cigarettes. Survey results out last week showed smoking among high school students was down to 9 percent, also a new low. In the early 1960s, roughly 42 percent of U.S. adults smoked. It was common nearly everywhere — in office buildings, restaurants, airplanes and even hospitals. The decline has coincided with a greater understanding that smoking is a cause of cancer, heart disease and other health problems. Anti-smoking campaigns, cigarette taxes and smoking bans are combining to bring down adult smoking rates, experts say. The launch of electronic cigarettes and their growing popularity has also likely played a role. E-cigarettes heat liquid nicotine into a vapor without the harmful by-products generated from burning tobacco. That makes them a potentially useful tool to help smokers quit, but some public health experts [...]

2018-06-20T10:10:36-07:00June, 2018|Oral Cancer News|

Nivolumab Plus Stereotactic Body Radiotherapy Fails To Improve Outcomes in Head and Neck Cancer

June 02, 2018 By: James Nam, PharmD Source: https://www.cancertherapyadvisor.com  CHICAGO—Although the addition of stereotactic body radiation therapy (SBRT) to nivolumab did not increase toxicity, it did not lead to any improvement in response rates or survival outcomes among patients with metastatic head and neck squamous cell carcinoma (HNSCC), according to an oral presentation at the American Society of Clinical Oncology 2018 Annual Meeting on Friday, June 1. Researchers sought to determine whether or not SBRT to a single lesion plus nivolumab would improve abscopal responses (tumor regression in non-irradiated lesions) and other outcomes among this patient population. In this phase 2 interventional study (ClinicalTrials.gov Identifier: NCT02684253), researchers randomly assigned 53 patients with metastatic HNSCC to receive nivolumab alone every 2 weeks or with SBRT between the first and second doses of nivolumab. The 2 study arms did not have any significant differences in terms of age, EBV/HPV viral status, primary site, or median lines of previous chemotherapy. The median follow-up was 12.8 months. Results showed that the overall response rate (ORR) was 26.9% (95% CI, 13.7-46.1) compared with 22.2% (95% CI, 10.6-40.8) in the nivolumab alone arm and nivolumab plus SBRT arm, respectively (P = .94). Patients receiving nivolumab alone did not have an evaluable median duration of response (DOR) compared with 9.3 months (95% CI, 55.2-not reached [NR]) among patients in the SBRT arm. The 1-year overall survival rate was 64% (95% CI, 47-88) in the nivolumab alone arm compared with 53% (95% CI, 36-79) in the nivolumab plus SBRT arm [...]

2018-06-04T10:12:12-07:00June, 2018|Oral Cancer News|

History of the Anti-Vaccine Movement – When Did the Anti-Vaccine Movement Really Start?

February 8th, 2018 By: Vincent Iannelli, MD Source: https://www.verywellfamily.com It is likely a surprise to many people that there has always been an anti-vaccine movement. It isn't something new that was created by Jenny McCarthy and Bob Sears. 18th Century Anti-Vaccine Movement In fact, the anti-vaccine movement essentially predates the first vaccine. Edward Jenner's first experiments with a smallpox vaccine began in 1796. Even before that, variolation as a technique to prevent smallpox was practiced for centuries in many parts of the world, including Africa, China, India, and the Ottoman Empire. In fact, Onesimus, his African slave, taught Cotton Mather about the technique in 1706. Lady Mary Wortley Montagu introduced inoculation to England, having learned about the practice in Turkey. As she encouraged others to inoculate and protect their children against smallpox, including the Royal Family, there was much debate. It is said that "Pro-inoculators tended to write in the cool and factual tones encouraged by the Royal Society, with frequent appeals to reason, the modern progress of science and the courtesy subsisting among gentlemen. Anti-inoculators purposely wrote like demagogues, using heated tones and lurid scare stories to promote paranoia." Were those the first vaccine debates? 19th Century Anti-Vaccine Movement Eventually, Edward Jenner's smallpox vaccine replaced variolation. Even though this was much safer than the previous practice and smallpox was still a big killer, there were still those who objected. Much of the resistance may have come because getting the smallpox vaccine in the UK in the 19th century was compulsory—you [...]

2018-06-04T10:08:53-07:00May, 2018|Oral Cancer News|

When Is Insurance Not Really Insurance? When You Need Pricey Dental Care.

May 21, 2018 By: David Tuller Source: https://khn.org I’m 61 years old and a San Francisco homeowner with an academic position at the University of California-Berkeley, which provides me with comprehensive health insurance. Yet, to afford the more than $50,000 in out-of-pocket expenses required for the restorative dental work I’ve needed in the past 20 years, I’ve had to rely on handouts — from my mom. This was how I learned all about the Great Divide between medicine and dentistry — especially in how treatment is paid for, or mostly not paid for, by insurers. Many Americans with serious dental illness find out the same way: sticker shock. For millions of Americans — blessed in some measure with good genes and good luck — dental insurance works pretty well, and they don’t think much about it. But people like me learn the hard way that dental insurance isn’t insurance at all — not in the sense of providing significant protection against unexpected or unaffordable costs. My dental coverage from UC-Berkeley, where I have been on the public health and journalism faculties, tops out at $1,500 a year — and that’s considered a decent plan. Dental policies are more like prepayment plans for a basic level of care. They generally provide full coverage for routine preventive services and charge a small copay for fillings. But coverage is reduced as treatment intensifies. Major work like a crown or a bridge is often covered only at 50 percent; implants generally aren’t covered at all. [...]

2018-05-21T09:32:46-07:00May, 2018|Oral Cancer News|

The Sate of Liquid Biopsy

Author:Pam Harrison Date: March 5, 2018 Source: Medscape.com So called "liquid biopsies" — which can detect circulating tumor DNA (ctDNA) in blood samples — are not yet ready for prime time in the diagnosis or management of early-stage or advanced solid tumors, a new expert review concludes. These assays are also not useful, outside of clinical trials, for monitoring patients for minimal residual disease following definitive treatment of cancer, nor for cancer screening, the expert review concludes. The review was prepared jointly by the American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) and was published online March 5 in the Journal of Clinical Oncology. "This is an area of great interest to both pathologists and oncologists, [and] it's also an area where we see a lot of commercial advertisement and a lot of enthusiasm from the public," Jason Merker, MD, PhD, cochair of the expert panel, who was representing the CAP, said in a statement. "We thought it was a good time to look at the literature and take an evidence-based approach to various uses for ctDNA assays," he added. "Like all new things in medicine, the use of ctDNA assays in routine cancer care requires evidence of clinical utility. At present, there is insufficient evidence of clinical validity and utility for the majority of ctDNA assays in advanced cancer, including those that interrogate a panel of genes," said Daniel F. Hayes, MD, coauthor of the review, who was representing ASCO. "What is promising is that this area [...]

2018-04-21T11:52:07-07:00March, 2018|Oral Cancer News|

Australia may become the first country to eliminate one form of cancer

Author: Brad Jones Date: March 8, 2018 Source: flipboard.com The International Papillomavirus Society has announced that Australia could become the first country to eliminate cervical cancer entirely. According to a new study, Australia's efforts to distribute a human papillomavirus (HPV) vaccine for free in schools have been a resounding success. The sexually transmitted infection causes 99.9 percent of cases of cervical cancer. In 2007, the Australian federal government began offering the vaccine to girls aged 12-13, and in 2013 it was made available to boys, too. Girls and boys outside of that age bracket but under nineteen are also entitled to two free doses of the vaccine. Between 2005 and 2015, the percentage of Australian women aged between 18 and 24 who had HPV dropped from 22.7 percent to just 1.1 percent. Immunization rates have increased further since 2015, contributing to what's being described as a "herd protection" effect. Coupled with a more advanced screening test that was introduced by the Australian government in December 2017, there are hopes that no new cases of cervical cancer will be reported within ten or twenty years. THE WORLD ISN'T CATCHING UP In the US, the HPV vaccine is not free. It can cost as much as $450 for the full regimen, according to the Association of Reproductive Health Professionals, although financial assistance is often available. In 2016, 78.6% of 15-year-old Australian girls, and 72.9% of 15-year-old Australian boys were vaccinated - but only 50% of American girls between 13 and 17, and 38% of American boys between 13 and [...]

2018-03-08T14:10:27-07:00March, 2018|Oral Cancer News|

Immunotherapy: beyond melanoma and lung cancer treatment

Author: David Crow Source: www.ft.com Date: March 4, 2018 In the late 1800s, William Coley, a surgeon in New York, developed what scientists now think was the first cancer immunotherapy. Coley noticed one of his patients, Fred Stein, had started recovering from cancer after catching a serious infection. The observation made him wonder whether the bacteria had somehow stimulated the patient’s immune system and recruited the body’s natural “resisting powers” in the fight against Mr. Stein’s tumours. The surgeon began treating inoperable cancer patients with bacterial injections — known as “Coley’s toxins” — and recorded some success, but his poorly documented findings were dismissed by contemporaries who favoured radiation and chemotherapy. Mr. Coley died in 1936 and his theories were all but forgotten: it would take almost 80 years for oncologists to take cancer immunotherapy seriously. Today, immunotherapies are among the world’s best selling drugs and they have dramatically improved the survival prospects for some of the sickest patients, especially those with melanoma and lung cancer. “Immunotherapy is here to stay,” says Jill O’Donnell-Tormey, chief executive of the Cancer Research Institute. “It's not just a blip, it’s not overhyped — I think it is going to become the standard of care for many cancer types.” The most common immunotherapy drugs are known as checkpoint inhibitors, which work by removing brakes in the immune system so the body can attack cancer. Their discovery was made possible by the research of James Allison, now a professor at the MD Anderson Cancer Center [...]

2018-03-05T11:28:31-07:00March, 2018|Oral Cancer News|
Go to Top